The Latest Psychedelics Articles from Streetwise Reports

Biotech at Good Entry Point for Investors, Analyst Says

Research Report
  ()
The company, focused on psychedelic-assisted psychotherapies to better treat addiction, is worth more than the CA$10 million the market is valuing it at, noted a Stifel report.
Tags:  Psychedelics

Potential ROI With German Biopharma Co. Notable

Research Report
  ()
This firm, with eight treatment candidates for mental health disorders in development, boasts a catalyst-rich next two months, noted a ROTH Capital Partners report.

Biopharma Target Price 10 Times Current

Research Report
  ()
Read to learn why ROTH Capital Partners gave Atai Life Sciences NV a Buy rating and a target price 10 times its current.
Tags:  Psychedelics

Opportunity for Investors Found in Psychedelics Space

Research Report
  ()
Treatment of alcohol use disorder with psychedelics plus therapy is effective, according to existing data, and the potential global market is large, noted an H.C. Wainwright & Co. report.
Tags:  Psychedelics

Biotech Co.'s Target Six Times Current Price

Research Report
  ()
One Phase 2 clinical trial showing LSD reduced symptoms of anxiety bodes well for other studies of LSD in this indication. In light of this, Oppenheimer & Co. gave this biotech company a target price that is over six times its current share price.
Tags:  Psychedelics

Showing Results: 1 to 5 of 5